(VIANEWS) – Two Harbors Investment Corp (TWO), Ellington Residential Mortgage REIT (EARN), Federal Realty Investment Trust (FRT) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio up until now. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. Two Harbors Investment Corp (TWO)
10500% Payout Ratio
Two Harbors Investment Corp. operates as a real estate investment trust (REIT) that focuses on investing in, financing, and managing residential mortgage-backed securities (RMBS), mortgage servicing rights, and other financial assets in the United States. Its target assets include agency RMBS collateralized by fixed rate mortgage loans, adjustable rate mortgage loans, and hybrid adjustable-rate mortgage (ARMs); and other assets, such as financial and mortgage-related assets, including non-agency securities and non-hedging transactions. The company qualifies as a REIT for federal income tax purposes. As a REIT, the company must distribute at least 90% of annual taxable income to its stockholders. Two Harbors Investment Corp. was incorporated in 2009 and is headquartered in Minnetonka, Minnesota.
Earnings Per Share
As for profitability, Two Harbors Investment Corp has a trailing twelve months EPS of $0.02.
PE Ratio
Two Harbors Investment Corp has a trailing twelve months price to earnings ratio of 678. Meaning, the purchaser of the share is investing $678 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.66%.
Sales Growth
Two Harbors Investment Corp’s sales growth for the next quarter is 1124.2%.
2. Ellington Residential Mortgage REIT (EARN)
274.29% Payout Ratio
Ellington Residential Mortgage REIT, a real estate investment trust, specializes in acquiring, investing in, and managing residential mortgage-and real estate-related assets. It acquires and manages residential mortgage-backed securities (RMBS), including agency pools and agency collateralized mortgage obligations (CMOs); and non-agency RMBS comprising non-agency CMOs, such as investment grade and non-investment grade. The company has elected to be taxed as a real estate investment trust. As a result, it would not be subject to corporate income tax on that portion of its net income that is distributed to shareholders. Ellington Residential Mortgage REIT was founded in 2012 and is based in Old Greenwich, Connecticut.
Earnings Per Share
As for profitability, Ellington Residential Mortgage REIT has a trailing twelve months EPS of $0.35.
PE Ratio
Ellington Residential Mortgage REIT has a trailing twelve months price to earnings ratio of 16.26. Meaning, the purchaser of the share is investing $16.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.54%.
Moving Average
Ellington Residential Mortgage REIT’s value is under its 50-day moving average of $6.11 and way below its 200-day moving average of $6.48.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 8% and positive 9.5% for the next.
Sales Growth
Ellington Residential Mortgage REIT’s sales growth is 0.4% for the ongoing quarter and negative 823.1% for the next.
Yearly Top and Bottom Value
Ellington Residential Mortgage REIT’s stock is valued at $5.69 at 01:23 EST, way under its 52-week high of $8.02 and way above its 52-week low of $5.09.
3. Federal Realty Investment Trust (FRT)
125.87% Payout Ratio
Federal Realty is a recognized leader in the ownership, operation and redevelopment of high-quality retail-based properties located primarily in major coastal markets from Washington, D.C. to Boston as well as San Francisco and Los Angeles. Founded in 1962, Federal Realty's mission is to deliver long-term, sustainable growth through investing in communities where retail demand exceeds supply. Its expertise includes creating urban, mixed-use neighborhoods like Santana Row in San Jose, California, Pike & Rose in North Bethesda, Maryland and Assembly Row in Somerville, Massachusetts. These unique and vibrant environments that combine shopping, dining, living and working provide a destination experience valued by their respective communities. Federal Realty's 106 properties include approximately 3,100 tenants, in 25 million square feet, and approximately 3,200 residential units. Federal Realty has increased its quarterly dividends to its shareholders for 54 consecutive years, the longest record in the REIT industry. Federal Realty is an S&P 500 index member and its shares are traded on the NYSE under the symbol FRT. For additional information about Federal Realty and its properties, visit www.federalrealty.com.
Earnings Per Share
As for profitability, Federal Realty Investment Trust has a trailing twelve months EPS of $3.44.
PE Ratio
Federal Realty Investment Trust has a trailing twelve months price to earnings ratio of 29.43. Meaning, the purchaser of the share is investing $29.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.45%.
Volume
Today’s last reported volume for Federal Realty Investment Trust is 690755 which is 0.85% below its average volume of 696709.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Federal Realty Investment Trust’s EBITDA is 65.41.
Previous days news about Federal Realty Investment Trust (FRT)
- According to Zacks on Thursday, 8 February, "We now look forward to the earnings releases of other retail REITs like Federal Realty Investment Trust (FRT Quick QuoteFRT – Free Report) and Realty Income (O Quick QuoteO – Free Report) , which are slated to report on Feb 12 and Feb 20, respectively."
- According to Zacks on Thursday, 8 February, "We now look forward to the earnings releases of other retail REITs like Federal Realty Investment Trust (FRT Quick QuoteFRT – Free Report) and Realty Income (O Quick QuoteO – Free Report) , which are slated to report on Feb 12 and Feb 20, respectively."
- According to Zacks on Friday, 9 February, "Investors are always looking for stocks that are poised to beat at earnings season and Federal Realty Investment Trust (FRT Quick QuoteFRT – Free Report) may be one such company. ", "Federal Realty Investment Trust price-eps-surprise | Federal Realty Investment Trust Quote"
4. Shenandoah Telecommunications Co (SHEN)
114.29% Payout Ratio
Shenandoah Telecommunications Company, together with its subsidiaries, provides a range of broadband communication services and cell tower colocation space in the Mid-Atlantic portion of the United States. Its Broadband segment offers broadband, video, and voice services to residential and commercial customers in Virginia, West Virginia, Maryland, Pennsylvania, and Kentucky, via hybrid fiber coaxial cable under the Shentel brand, fiber optic services under the Glo Fiber brand, and fixed wireless network services under the Beam brand name. This segment leases fiber and provides Ethernet and wavelength fiber optic services. In addition, the company offers voice and digital subscriber line telephone services. The company's Tower segment owns 220 cell towers and leases colocation space on the towers. Shenandoah Telecommunications Company was founded in 1902 and is based in Edinburg, Virginia.
Earnings Per Share
As for profitability, Shenandoah Telecommunications Co has a trailing twelve months EPS of $0.07.
PE Ratio
Shenandoah Telecommunications Co has a trailing twelve months price to earnings ratio of 297.57. Meaning, the purchaser of the share is investing $297.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.56%.
5. Bristol (BMY)
59.84% Payout Ratio
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Bristol has a trailing twelve months EPS of $3.86.
PE Ratio
Bristol has a trailing twelve months price to earnings ratio of 12.85. Meaning, the purchaser of the share is investing $12.85 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.72%.
Sales Growth
Bristol’s sales growth is negative 1.9% for the ongoing quarter and 0.9% for the next.
Volume
Today’s last reported volume for Bristol is 10115200 which is 35.14% below its average volume of 15596100.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 15.9% and a negative 13.7%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.6%, now sitting on 45.01B for the twelve trailing months.
Previous days news about Bristol (BMY)
- According to Zacks on Thursday, 8 February, "Some KRAS inhibitors available in the market are Amgen’s Lumakras (sotorasib) and Mirati Therapeutics’, now part of Bristol Myers (BMY Quick QuoteBMY – Free Report) , Krazati (adagrasib)."
- Bristol myers' (bmy) opdivo label expansion filings get accepted. According to Zacks on Thursday, 8 February, "Bristol Myers Squibb Company price-consensus-chart | Bristol Myers Squibb Company Quote", "In the past year, shares of Bristol Myers have plunged 32% compared with the industry’s 11.7% decline."
- According to Zacks on Thursday, 8 February, "It has been a busy week for the biotech sector, with earnings from bigwigs like Gilead Sciences (GILD Quick QuoteGILD – Free Report) , Bristol Myers (BMY Quick QuoteBMY – Free Report) and Amgen (AMGN Quick QuoteAMGN – Free Report) , among others. "
- According to Zacks on Thursday, 8 February, "Notable names include Amazon, Meta, Apple, Chevron, ExxonMobil, Merck, and Bristol Myers Squibb, collectively propelling the growth rate for Q4."
- The zacks analyst blog highlights gilead sciences, bristol myers, Amgen, morphysys and regenxbio. According to Zacks on Friday, 9 February, "Stocks recently featured in the blog include: Gilead Sciences (GILD Quick QuoteGILD – Free Report) , Bristol Myers (BMY Quick QuoteBMY – Free Report) , Amgen (AMGN Quick QuoteAMGN – Free Report) , Morphysys (MOR Quick QuoteMOR – Free Report) and REGENXBIO Inc. (RGNX Quick QuoteRGNX – Free Report) .", "It has been a busy week for the biotech sector, with earnings from bigwigs like Gilead Sciences, Bristol Myers and Amgen, among others. "
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1%, now sitting on 1 for the twelve trailing months.
Volume
Today’s last reported volume for 1 is 1 which is 1% above its average volume of 1.
Sales Growth
1’s sales growth is 1% for the current quarter and 1% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 1% and 1%, respectively.
